Conversion from calcineurin inhibitors to sirolimus of recipients with chronic kidney graft disease grade III for a period 2003–2011

Ljiljana Bozidar Ignjatovic*,; Rajko Hrvačevic; Dragan Jovanović; Zoran Kovačević; Neven Vavić; Violeta Rabrenović; Aleksandar Tomić; Predrag Aleksić; Biljana Draškovć-Pavlović; Aleksandar Dujić†.; Željiko Karan; Djoko Maksić

doi:10.2298/1383

Ljiljana Bozidar Ignjatovic*, Medical Military Academy, Clinic of Nephrology
Rajko Hrvačevic Fresenius Medical Care
Dragan Jovanović Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Zoran Kovačević Medical Military Academy, Clinic of Nephrology
Neven Vavić Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia
Violeta Rabrenović Medical Military Academy, Clinic of Nephrology
Aleksandar Tomić Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Predrag Aleksić Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Biljana Draškovć-Pavlović Faculty of Medicine of the Military Medical Academy, University of Defence, Belgrade, Serbia
Aleksandar Dujić†. Military Medical Academy, Institute for Medical Investigations
Željiko Karan Center for Hospital Information System, Military Medical Academy, Belgrade, Serbia
Djoko Maksić Clinic of Nephrology, Military Medical Academy, Belgrade, Serbia

DOI: https://doi.org/10.2298/1383

Abstract

Background/Aim. Tremendous breakthrough in solid organ transplantation was made with the introduction of calcineurin inhibitors (CNI). At the same time, they are potentially nephrotoxic drugs with influence on onset and progression of renal graft failure. The aim of this study was to evaluate the outcome of a conversion from CNI-based immunosuppressive protocol to sirolimus (SRL) in recipients with graft in chronic kidney disease (CKD) grade III and proteinuria below 500 mg/day. Methods. In the period 2003–2011 24 patients (6 famale and 18 male), mean age 41 ± 12.2 years, on triple immunosuppressive therapy: steroids, antiproliferative drug [mycophenolate mofetil (MMF) or azathiopirine (AZA)] and CNI were switched from CNI to SRL and followe-up for 76 ± 13 months. Nine patients (the group I) had early postransplant conversion after 4 ± 3 months and 15 patients (the group II) late conversion after 46 ± 29 months. During the regular outpatient controls we followed graft function through the serum creatinine and glomerular filtration rate (GFR), proteinuria, lipidemia and side effects. Results. Thirty days after conversion, in all the patients GFR, proteinuria and lipidemia were insignificantly increased. In the first two post-conversion months all the patients had at least one urinary or respiratory infection, and 10 patients reactivated cytomegalovirus (CMV) infection or disease, and they were successfully treated with standard therapy. After 21 ± 11 months 15 patients from both groups discontinued SRL therapy due to reconversion to CNI (10 patients) and double immunosuppressive therapy (3 patients), return to hemodialysis (1 patient) and death (1 patient). Nine patients were still on SRL therapy. By the end of the follow-up they significantly improved GFR (from 53.2 ± 12.7 to 69 ± 15 mL/min), while the increase in proteinuria (from 265 ± 239 to 530.6 ± 416.7 mg/day) and lipidemia (cholesterol from 4.71 ± 0.98 to 5.61 ± 1.6 mmol/L and triglycerides from 2.04 ± 1.18 to 2.1 ± 0.72 mmol/L) were not significant. They were stable during the whole follow-up period. Ten patients were reconverted from SRL to CNI due to the abrupt increase of proteinuria (from 298 ± 232 to 1639 ± 1641/mg day in 7 patients), rapid growth of multiple ovarian cysts (2 patients) and operative treatment of persisted hematoma (1 patient). Thirty days after reconversion they were stable with an insignificant decrease in GFR (from 56.10 ± 28.09 to 47 ± 21 mL/min) and significantly improved proteinuria (from 1639 ± 1641 to 529 ± 688 mg/day). By the end of the follow-up these patients showed nonsignificant increase in the serum creatinine (from 172 ± 88 to 202 ± 91 mmol/L), decrease in GFR (from 56.10 ± 28.09 to 47 ± 21 mL/day) and increased proteinuria (from 528.9 ± 688 to 850 ± 1083 mg/min). Conclusion. In this small descriptive study, conversion from CNI to SRL was followed by an increased incidence of infections and consecutive 25–50% dose reduction in the second antiproliferative agent (AZA, MMF), with a possible influence on the development of glomerulopathy in some patients, which was the major reason for discontinuation of SRL therapy in the 7 (29%) patients. Nine (37.5%) of the patients experienced the greatest benefit of CIN to SRL conversion without serious post-conversion complications.

Key words:

kidney transplantation; graft survival; kidney failure, chronic; calcineurin; sirolimus; disease progression.

Author Biographies

Ljiljana Bozidar Ignjatovic*,, Medical Military Academy, Clinic of Nephrology

Clinic Of Nephrologu I

nephrologyst

Aleksandar Dujić†., Military Medical Academy, Institute for Medical Investigations

retired

References

Schena FP, Pascoe MD, Alberu J, del Carmen Rial M, Oberbauer R, Brennan DC, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87(2): 233−42.

Hanto DW, Chudzinski R. What does the CONVERT trial really tell us about conversion from calcineurin inhibitors to sirolimus? Transplantation 2009; 87(2): 164−5.

Flechner SM. Sirolimus in kidney transplantation indications and practical guidelines: de novo sirolimus-based therapy without calcineurin inhibitors. Transplantation 2009; 87(8 Suppl): S1−6.

Larson TS, Dean PG, Stegall MD, Griffin MD, Textor SC, Schwab TR, et al. Complete avoidance of calcineurin inhibitors in renal transplantation: a randomized trial comparing sirolimus and tacrolimus. Am J Transplant 2006; 6(3): 514−22.

Saurina A, Campistol JM, Piera C, Diekmann F, Campos B, Campos N, et al. Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria. Nephrol Dial Transplant 2006; 21(2): 488−93.

Weir MR, Blahut S, Drachenburg C, Young C, Papademitriou J, Klassen DK, et al. Late calcineurin inhibitor withdrawal as a strategy to prevent graft loss in patients with suboptimal kidney transplant function. Am J Nephrol 2004; 24(4): 379−86.

Abramowicz D, Hadaya K, Hazzan M, Broeders N, Hoang AD, Ghisdal L, et al. Conversion to sirolimus for chronic renal allograft dysfunction: risk factors for graft loss and severe side effects. Nephrol Dial Transplant 2008; 23(11): 3727−9.

Diekmann F, Budde K, Oppenheimer F, Fritsche L, Neumayer HH, Campistol JM. Predictors of success in conversion from calci-neurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4(11): 1869−75.

Diekmann F, Campistol JM. Conversion from calcineurin inhibitors to sirolimus in chronic allograft nephropathy: benefits and risks. Nephrol Dial Transplant 2006; 21(3): 562−8.

Wali RK, Mohanlal V, Ramos E, Blahut S, Drachenberg C, Papadimitriou J, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7(6): 1572−83.

Amer H, Cosio FG. Significance and management of proteinuria in kidney transplant recipients. J Am Soc Nephrol 2009; 20(12): 2490−2.

Webster AC, Lee VW, Chapman JR, Craig JC. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: a systematic review and meta-analysis of randomized trials. Transplantation 2006; 81(9): 1234−48.

Salgo R, Gossmann J, Schöfer H, Kachel HG, Kuck J, Geiger H, et al. Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial. Am J Transplant 2010; 10(6): 1385−93.

Alberú J, Pascoe MD, Campistol JM, Schena FP, Rial Mdel C, Po-linsky M,et al. Lower malignancy rates in renal allograft reci-pients converted to sirolimus-based, calcineurine inhibitor-free immunotherapy: 24-month results from the CONVERT trial. Transplantation 2011; 92(3): 303−10.

Monaco AP. The role of mTOR inhibitors in the management of posttransplant malignancy. Transplantation 2009; 87(2): 157−63.

Kasiske BL, Guijarro C, Massy ZA, Wiederkehr MR, Ma JZ. Cardiovascular disease after renal transplantation. J Am Soc Nephrol 1996; 7(1): 158−65.

Weir MR, Wali RK. Minimizing the risk of chronic allograft nephropathy. Transplantation 2009; 87(8 Suppl): S14−8.

Ruiz JC, Campistol JM, Sánchez-Fructuoso A, Rivera C, Oliver J, Ramos D,et al. Increase of proteinuria after conversion from calcineurin inhibitor to sirolimus-based treatment in kidney transplant patients with chronic allograft dysfunction. Nephrol Dial Transplant 2006; 21(11): 3252−7.

Weir MR, Diekmann F, Flechner SM, Lebranchu Y, Mandelbrot DA, Oberbauer R, et al. mTOR inhibition: the learning curve in kidney transplantation. Transpl Int 2010; 23(5): 447−60.

Letavernier E, Bruneval P, Mandet C, Duong Van Huyen JP, Péraldi MN, Helal I, et al. High sirolimus levels may induce focal segmental glomerulosclerosis de novo. Clin J Am Soc Nephrol 2007; 2(2): 326−33.